Supplementary materials

1. Hormone form and dosage

The table below displays the form and dosage of GAHT used by the study participants, at the start of GAHT (e.g. after the baseline measurement) and at the 3-month follow up.

		Transmasculine participants (n = 38)		Transfeminine participants (n = 35)	
Measurement		Start of GAHT n = 36	At 3 month follow-up	Start of GAHT n = 32	At 3 month follow-up
			n = 26		n = 24
Cycle regulation use (n,	Progestin only – oral	4 (11%)	3 (12%)	-	-
%)	Progestin only – non-oral methods ^{1.}	8 (22%)	3 (12%)	-	-
	Estradiol and progestin – combined oral contraceptives	6 (17%)	0 (0%)	-	-
	None	18 (50%)	6 (23%)	-	-
Testosterone form (n, %)	Transdermal	32 (89%)	19 (73%)	-	-
	Intramuscular – short- acting (esters)	4 (11%)	2 (8%)	-	-
	Intramuscular – long- acting (undecanoate)	0 (0%)	5 (20%)	-	-
Estrogen form (n, %)	Oral	-	-	17 (53%)	14 (46%)
	Transdermal – gel	-	-	3 (9%)	3 (13%)
	Transdermal – spray	-	-	0 (0%)	0 (0%)
-	Transdermal – patches	-	-	12 (38%)	7 (29%)
Anti-androgen form (n,	GnRH analogues – short-	-	-	25 (78%)	13 (54%)
6)	acting				
	GnRH analogues – long-	-	-	4 (13%)	8 (33%)
	acting				
	Cyproterone actate	-	-	3 (9%)	3 (13%)

2. Smartsleep mode

The table below displays the outcomes stratified by sleep device setting and the estimated differences between the inactive and the active mode. Analyses show no significant differences between the active and inactive mode of the device.

Table S2: sleep architecture during GAHT – with main predictor for devices in active mode.							
	TM			TF			
	Means and		Estimated	Means and SD or median		Estimated	
	median and	d IQR	difference	and IQR		difference active	
			active vs.			vs. inactive mode a.	
			inactive mode a.				
Setting	Inactive	Active		Inactive	Active		
Measurement	Baseline:	Baseline:	Beta, 95%	Baseline: n	Baseline: n	Beta, 95%	
weeks	n = 33	n = 3	confidence	= 31	= 1	confidence	
	3MO: n =	3MO: n =	interval, p-value	3MO: n =	3MO: n = 1	interval, p-value	
	15	11		23			
SOL (minutes)	17.8	20.02	-15.5% (-39.1%	13.98 (7.29	16.87	3.21% (-10.95 to	
	(7.96 to	(7.96 to	to 17.7%)	to 27.25)	(12.22 to	19.58)	
	33.1)	36.7)	P = 0.31		26.85)	P = 0.68	
TST (hours)	7.3 (1.4)	7.6 (1.6)	0.144 (-0.30 to	6.49 (1.33)	6.64 (0.67)	0.6594 (-0.251 to	
			0.59)			1.559)	
			P = 0.53			P = 0.15	
WASO (minutes)	20.27	21.0 (15.4	4.2% (-18.7 to	15.79 (9.83	21.66	-9.998% (-47.56 to	
	(12.8 to	to 28.1)	33.4) p = 0.75	to 37.54)	(11.18 to	54.47)	
	38.4)				32.1)	P = 0.70	
NRI	1 (0 to 2)	1 (0 to 2)	6.96% (-10.4%	1 (0 to 1.5)	1 (0 to 2)	-17.26% (-44.38 to	
			to 27.8%)			23.26)	
			P = 0.46			P = 0.35	
NRA	27 (21 to	26.5 (19	-3.1% (-17.6 to	27 (41 to	40 (15.5 to	- 13.80% (-41.08 to	
	40)	to 43)	13.9)	18)	53.5)	26.17)	
			P = 0.70			P = 0.45	
SWS (minutes)	87 (31)	93 (32)	-1.5 (-5.5 to	86 (30)	82 (23)	-6.31 (-21.53 to	
			8.59)			8.96)	
			P = 0.67			P = 0.42	
% SWS	20.0%	21.0%	-0.04% (-1.88	22.6 (8.05)	20.82 (7.02)	-4.3247% (-9.2956	
	(7.3%)	(8.0%)	to 1.80)			to 0.692)	
			P = 0.95			P = 0.091	
REM sleep	118.9	119.1	-9.90 (-23.27 to	114.26	106.91	7.938 (-20.63 to	
duration	(45.5)	(38.9)	3.49)	(42.9)	(19.67)	36.28)	
(minutes)			P = 0.149			P = 0.58	

REM sleep	82 (33.5	68 (28.8	-1.9% (-29.6 to	81.00 (22.5	89.0 (39.5	29.74% (42.66 to
latency (minutes)	to 125.5)	to 101.5)	39.3)	to 111.5)	to 95.0)	90.51)
			P = 0.95			P = 0.53

^{a.} Analyzed using a linear mixed model with measurement phase and device setting as fixed predictors and a random intercept per participant, with inactive mode as the reference category.

3. Participation and non-participation in objective sleep measurements

The table below displays demographic descriptions and questionnaire outcomes of participants who contributed sleep device measurements to the final dataset and participants who did not. It is possible that participants took part in the objective sleep measurements, but that the measurements were of low quality and that they were excluded, which means the participant's measurements are therefore not present in the final dataset.

Table S3. Demographic and clinical characteristics of participants opting in and out of sleep device measurements. IQR = Interquartile range.									
		Not present in objective sleep measurements	Present in baseline objective sleep measurements only	Present in 3MO objective sleep measurements only	Present in baseline and 3MO				
n		26	23	5	45				
Age	Median, IQR	22 (20 to 24.5)	24 (21.5 to 26)	28 (19 to 30)	24 (22 to 27)				
Group (n, %)	TM	13 (50%)	12 (52%)	2 (40%)	24 (53%)				
	TF	13 (50%)	11 (48%)	3 (50%)	21 (47%)				
Psychotropic medication use (n, %)	Yes	5 (19%)	2 (9%)	1 (20%)	9 (20%)				
	No	21 (81%)	21 (91%)	4 (80%)	36 (80%)				
	Scores at baseline								
ISI scores (range 0 to 28)	Median IQR missings (n)	7.5 4.75 to 10.25 2	5.5 3.25 to 10.5 1	6.0 4.0 to 6.0 0	6.0 3.0 to 9.0 0				
PSQI scores (range 21)	Median IQR missings (n)	7 4.25 to 9.0 4	5 4 to 9 4	4 4 to 6 0	6 4 to 8 4				
IDS-SR scores (range 0 to 84)	Median IQR missings (n)	15.5 10 to 26 4	12 8 to 25.75 1	9 8 to 25 0	12 8 to 21 0				
PSS scores (range 0 to 40)	Median IQR missings (n)	13 9.5 to 16.25 2	12 8.25 to 17 1	11 6 to 13 0	10 8 to 16 0				